CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated
- 332 Downloads
Although GC (gemcitabine and cisplatin) chemotherapy remains an effective method for treating bladder cancer (BCa), chemoresistance is a major obstacle in chemotherapy. In this study, we determined whether gemcitabine resistance correlates with migratory/invasive potential in BCa and whether this relationship is regulated by the cylindromatosis (CYLD)-Livin module. First, we independently investigated the correlation of CYLD/Livin and gemcitabine resistance with the potential for tumor migration and invasiveness. Second, we found that co-transfected CYLD and Livin dramatically improved sensitivity to gemcitabine chemotherapy and decreased migration/invasion potential. Next, we determined that CYLD may regulate Livin by the NF-κB-dependent pathway. We also found that CYLD overexpression and Livin knockdown might improve gemcitabine chemosensitivity by decreasing autophagy and increasing apoptosis in BCa cells. Finally, the effects of CYLD-Livin on tumor growth in vivo were evaluated. Our study demonstrates that CYLD-Livin might represent a potential therapeutic for chemoresistant BCa.
KeywordsGemcitabine Cylindromatosis (CYLD) Livin Bladder cancer (BCa) Autophagy
This work was supported by the Shandong Key Research and Development Project (No. 2015GSF118055 ), Medicine and Healthcare Technology Development Project of Shandong Province (No. 2014WS0341), and Natural Science Foundation of Shandong Province (No. 2014ZRB14513 and 2014ZRB14081).
Compliance with ethical standards
The study had obtained approval from the Committee on Animal Research of Shandong Provincial Hospital of Shandong University, and our care was in accordance with institutional guidelines.
Conflicts of interest
- 5.Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J, Yuan P, Zhong Z, Li Q, Jia H, Sun J, Chen Z, Guo AY. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2012;40(12):5201–14.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Urbanik T, Koehler BC, Wolpert L, Elssner C, Scherr AL, Longerich T, Kautz N, Welte S, Hovelmeyer N, Jager D, Waisman A, Schulze-Bergkamen H. CYLD deletion triggers nuclear factor-kappaB-signaling and increases cell death resistance in murine hepatocytes. World J Gastroenterol. 2014;20(45):17049–64.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Zhang Y, Huang H, Zhou H, Du T, Zeng L, Cao Y, Chen J, Lai Y, Li J, Wang G, Guo Z. Activation of nuclear factor kappaB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer. Cancer-Am Cancer Soc. 2014;120(20):3208–18.Google Scholar
- 16.Li M, Gao P, Zhang J. Crosstalk between autophagy and apoptosis: potential and emerging therapeutic targets for cardiac diseases. Int J Mol Sci. 2016;17(3).Google Scholar
- 26.Hamacher-Brady A, Brady NR. Bax/Bak-dependent, Drp1-independent targeting of X-linked inhibitor of apoptosis protein (XIAP) into inner mitochondrial compartments counteracts Smac/DIABLO-dependent effector caspase activation. J Biol Chem. 2015;290(36):22005–18.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Gungor C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, Yekebas E, Bockhorn M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011;71(14):5009–19.CrossRefPubMedGoogle Scholar
- 34.Maseki S, Ijichi K, Tanaka H, Fujii M, Hasegawa Y, Ogawa T, Murakami S, Kondo E, Nakanishi H. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br J Cancer. 2012;106(6):1196–204.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17(8):2350–60.CrossRefPubMedGoogle Scholar
- 36.Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Ding Z, Liu Y, Yao L, Wang D, Zhang J, Cui G, Yang X, Huang X, Liu F, Shen A. Spy1 induces de-ubiquitinating of RIP1 arrest and confers glioblastoma’s resistance to tumor necrosis factor (TNF-alpha)-induced apoptosis through suppressing the association of CLIPR-59 and CYLD. Cell Cycle. 2015;14(13):2149–59.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Jiang Y, Han Y, Sun C, Han C, Han N, Zhi W and Qiao Q. Rab23 is overexpressed in human bladder cancer and promotes cancer cell proliferation and invasion. Tumour Biol 2015.Google Scholar
- 49.Lv L, Liu HG, Dong SY, Yang F, Wang QX, Guo GL, Pan YF and Zhang XH. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumour Biol 2016.Google Scholar
- 50.Xu R, Liu S, Chen H and Lao L. MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy. Oncol Rep 2015.Google Scholar
- 54.Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, Liu T, Wang D, Ge H, Mo SL. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015;5(6):554–63.CrossRefPubMedPubMedCentralGoogle Scholar